January 7, 2025, Rochester, MN – Emmyon Inc. is proud to share the news of the commercial launch of Virbac’s URSOLYX™ Soft Chews, an innovative new product for muscle health in dogs based on Emmyon’s ursolic acid technology.

URSOLYX™ Soft Chews were developed through a collaboration between Emmyon and Virbac, a global leader in animal health. This first-in-class muscle support product provides an important new nutritional approach to help maintain healthy skeletal muscle and activity in dogs, and marks a first step in translating Emmyon technology to animal health.

For additional information on this exciting new product, please see the URSOLYX™ Soft Chews video, website, and press release from Virbac.

January 24, 2024, Rochester, MN – We are pleased to announce the publication of an important new study that Emmyon conducted in collaboration with Virbac Corporation, an international leader in nutritional and pharmaceutical products for animal health.  The article was published in the veterinary journal Animals and can be freely obtained here or at the journal website: https://www.mdpi.com/2076-2615/14/2/186

Our study focused on skeletal muscle health in dogs, who often suffer from significant muscle wasting and functional deficits when they become older, ill, or injured.  To address this problem, we developed a novel canine dietary supplement (soft chew) containing a coated version of ursolic acid, a natural dietary compound that Emmyon scientists previously discovered and patented for skeletal muscle health.  Through randomized, placebo-controlled studies in old dogs with age-related skeletal muscle atrophy (sarcopenia), we found that the ursolic acid soft chew is safe and well tolerated by dogs, and it generates numerous beneficial molecular changes in skeletal muscle mRNA expression, leading to striking improvements in exercise participation and performance. These exciting results identify a new nutritional approach for maintaining healthy skeletal muscle and activity in dogs.

March 7, 2023, Rochester, MN – Emmyon is pleased to announce that it has received a new Phase II Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI), a division of the U.S. National Institutes of Health (NIH).  The funding will support development of therapeutics for cancer-induced skeletal muscle wasting.  We are very grateful to the NCI and the NIH for their support of these efforts.

December 2022, Rochester, MN – We are pleased to announce that Emmyon, Inc. and CJ Food & Nutrition Tech signed an exclusive licensing agreement establishing a strategic partnership.  The technical and commercial collaboration will result in the global launch of several nutraceutical and dietary supplement products that can inhibit muscle atrophy while improving strength and endurance.

> View the Press Release

December 17, 2020, Coralville, IA – Emmyon is pleased to announce that it has received a new Phase II Small Business Innovation Research (SBIR) award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the U.S. National Institutes of Health (NIH).  The funding will support development of novel pharmaceutical compounds for skeletal muscle atrophy, obesity and type 2 diabetes.  We’re very grateful to NIAMS and the NIH for their continued support of these efforts.

August 31, 2020, Coralville, IA – Emmyon is honored and grateful to announce that it has been included in the Small Business Showcase of the National Institute on Aging (NIA), a division of the U.S. National Institutes of Health. Please use this link to visit the NIA Small Business Showcase and read about the work Emmyon is conducting.